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The search for the mutant genes for monogenic disorders
has been a spectacular success. This was accomplished
because of the mapping and sequencing of the human
genome, the determination of the sequence variability, the
collection of well-characterized families with mendelian
disorders, the development of statistical methods for link-
age analysis, and laboratory methods for mutation search.
The challenge of the genetic medicine is now to decipher
the nucleotide sequence variants that predispose to com-
mon complex, polygenic phenotypes. The methodology for
this challenge is in development and constant evolution. It
is anticipated that, in the next 10 to 20 years, susceptibility
alleles for these common disorders will be identified.
he principal aim of the field of genetic medi-
cine is to discover the links between nucleotide sequence
variation in the human genome and the various human
phenotypes.The methodologies of linkage analysis and
mutation detection,along with progress in the mapping
and sequencing of the human genome and that of model
organisms,resulted in a plethora of exciting discoveries
concerning mutant alleles of genes and their related phe-
notypes. In this review, I will briefly summarize some
general principles regarding the search for genes (more
specifically, mutant alleles of these genes) that either
cause the various human genetic disorders or confer
predisposition to common,complex phenotypes.
Monogenic disorders
There are a large number of phenotypes (each of which
is rare in the population) due to abnormal mutant alle-
les of single genes. These disorders are usually called
monogenic since there is one gene of paramount impor-
tance related to the development of the phenotype;con-
sequently, these phenotypes show a mendelian mode
of inheritance.For a particular disorder,the mapping of
the responsible gene could easily be determined by
studying the transmission of polymorphic markers
within a family. Positional candidate gene–cloning
strategies could then be employed to identify the
responsible gene by virtue of mutations (nucleotide
sequence variants) present in a patient’s DNA and not
in controls.The genetic methodology identified a route
to understanding the molecular basis of disease, which
otherwise seemed intractable. On May 25, 2001, the
knowledge-based database OMIM (Online Mendelian
Inheritance in Man)
1,2 contained 1168 mutant genes
linked to human monogenic disorders. Several notable
examples of neurological disorders are shown in Table I,
which lists disease genes, their corresponding pheno-
types, and the years of the linkage mapping and their
positional cloning. The first mutant gene–disease link
discovered by positional cloning strategies was that of
chronic granulomatous disease in 1986.
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State of the artThe work of numerous investigators in both academia
and the biotechnology industry over the last 20 years or
so has provided the infrastructure necessary to perform
studies of linkage mapping and gene identification of
genetic disorders.A large number of polymorphic mark-
ers due to variable units of short sequence repeats
(SSRs) have been identified throughout the entire
genome and used to create linkage maps of all human
chromosomes.These highly polymorphic markers in turn
provided the tools to localize the unknown disease-
related genes to intervals of the genome.The most com-
mon of these SSRs are dinucleotide repeats such as
(GT)n or (AT)n. Dense linkage maps that determined
the position, order, and distance of adjacent SSRs have
been produced by genotyping the DNAs of appropri-
ate large families including those collected and distrib-
uted by CEPH (Centre d’Étude de Polymorphism
Humain).
3 A “draft” sequence of the entire human
genome has been obtained and is publicly available.
4,5
Approximately 40% of this sequence is already finished
(ie, of high quality, ordered, and practically gapless),
including that of the chromosomes 22 and 21.
6,7 The
availability of the nucleotide sequence has two impor-
tant consequences for identifying disease loci. First, the
recognition of a total of approximately 35 000 genes will
now greatly facilitate and accelerate gene–disease
matchmaking.Second,the discovery of more than 2 mil-
lion single nucleotide polymorphisms (SNPs)
5,8 will likely
result in the recognition of the functional nucleotide
sequence variability that is associated with common
complex phenotypes.
The story of positional identification 
of disease-related alleles
Let me now describe a typical project to identify the
mutant gene associated with a monogenic disorder
(Figure 1),for example,the autosomal dominant Hunt-
ington disease gene.Dominant means that a mutation
in only one allele of an autosomal gene is needed in
order to manifest the disorder. In contrast, in a reces-
sive disease,mutations in both alleles of an autosomal
gene are needed for the phenotypic expression of the
disease. Mutations in genes on the X or Y sex chro-
mosomes are associated with X- or Y-linked pheno-
types. However, no matter the mode of inheritance,
the general strategy to identify the causative gene
mutation(s) is similar.
Collection of families 
The initial phase of the project is to identify families with
the precise phenotypic characteristics of the disease,and
establish that the number of individuals available for
study provides the appropriate power in linkage analysis
to identify the disease gene location. The collection of
samples from affected and unaffected members of the
families is then justified, after approval of the study by
the local human experimentation ethics committees and
informed consent.For Huntington disease,members of a
large family from Maracaibo,Venezuela,were collected,
9
but the biomedical literature is full of other interesting
family collections from different parts of the world and
different geoethnic communities. The best population
groups for rare autosomal recessive disorders are those
in which consanguineous marriages are common, or
those originated from a few founders. I wish to empha-
size the importance of accurate diagnosis of affected and
nonaffected individuals in order to perform errorless
linkage analysis.Aspects of the phenotype that have to
be taken into account include the age of onset and clini-
cal variation;the participation of a clinical expert is there-
fore of paramount importance in the development and
success of the project.
Linkage analysis 
The next phase is the performance of linkage analysis to
localize the yet unknown “disease gene” to a small
genomic region. This linkage analysis is based on the
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Gene Disease Mapping Cloning
HD Huntington chorea 1983 1993
NF1 Neurofibromatosis, type I 1987 1991
AT1 Ataxia-telangiectasia 1988 1995
SCN4A Hyperkalemic periodic paralysis 1990 1991
VHL Von Hippel-Lindau syndrome 1988 1993
DRPLA Dentatorubral-pallidoluysian atrophy 1993 1993
SMN1 Spinal muscular atrophy 1990 1995
SOD1 Amyotrophic lateral sclerosis, familial 1991 1993
PS1 Alzheimer’s disease, early-onset 1992 1995
PS2 Alzheimer’s disease, early-onset 1995 1995
FA Friedreich ataxia 1988 1996
PARK2 Parkinson’s disease, juvenile 1997 1998
Table I. Partial list of selected mutant genes that cause monogenic
neurological disorders.9
identification of DNA polymorphic markers that coseg-
regate with the disease phenotype. The DNA markers,
which constitute part of the normal nucleotide variabil-
ity of the genome, usually fall into two categories as
mentioned: the SSRs and the SNPs. For the linkage
analysis studies,the most useful markers are SSRs since
they are highly polymorphic.There are more than two
different (usually six) alleles per SSR marker in the pop-
ulation,and they are therefore informative in the major-
ity of the families. Most of the successful linkage map-
ping studies have used approximately 300 such markers
equally distributed throughout the genome with an aver-
age interval of 10 cM, or 10% recombination between
adjacent markers. Note that this distance is measured
in genetic terms, ie, in recombination units in human
meiosis;1 cM on average corresponds to approximately
1000 kb or 10
6 nucleotides of DNA.After the use of suf-
ficient markers,the success of a linkage mapping project
in a monogenic phenotype depends on:
• The size of the families and the DNAs available for study.
It is imperative to perform a linkage simulation analy-
sis of the available sample to determine if there is suf-
ficient statistical “power”to detect linkage.
• The accuracy of the diagnosis. Problems arise when
affected individuals are categorized as normal or vice
versa (due to inability to detect the manifestations of
the phenotype, or reduced “penetrance,” ie, the
absence of phenotype in spite of the presence of the
mutant gene or late onset of the phenotypic charac-
teristics).
• The extent of the genetic heterogeneity of the phenotype.
It is much easier to map the disease locus if the pheno-
type is always due to mutations in the same gene. In
contrast,it is much more difficult to map loci for disor-
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Figure 1. Schematic representation of a genetic (map-based) approach to identify mutant alleles involved in monogenic and complex phenotypes.
The human genome is shown as a double straight line in the middle. The top panel shows a simplified strategy for monogenic disorders.
The responsible gene is mapped by linkage analysis to a small genomic interval (shown in red); subsequently, positional identification of
the pathogenic mutation is based on the nucleotide sequence information. The bottom panel shows a simplified strategy for complex,
polygenic disorders and traits. The predisposing alleles are mapped by linkage and association studies to several large regions of the
genome (shown in blue). It is expected that sequence-based association studies will uncover some of the predisposing alleles. SNP, sin-
gle nucleotide polymorphism.
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ders/phenotypes that result from mutant alleles of
more than one gene. An example of genetic homo-
geneity is Huntington disease, in which all affected
pedigrees are due to mutations in the same gene on
chromosomal region 4p.
10 In contrast,tuberous sclero-
sis shows genetic heterogeneity. There are two genes,
TSC1 and TSC2 on chromosomes 9 and 16, respec-
tively; mutations in each result in the same phenotype
of tuberous sclerosis.
11
The next step after the localization of a disease-related
locus to a particular genomic interval is to narrow down
this region to an area of approximately 1 to 2 megabases
(Mb) (1000 000-2000 000 nucleotides). Data provided
by the preliminary annotation of the human genome
sequence indicate that,on average,there are 9 genes per
megabase,with a range between different chromosomes
from 5 to 23.
4,5
The narrowing down of the "critical region" is there-
fore important and can generally be achieved by two
methods. The first is to identify critical recombination
events between certain DNA markers and the disease
phenotype in the families examined.This is achieved by
the addition of affected families and by studying a large
number of markers in the critical region. It is advisable
to rely mostly on recombinants in the DNAs of affected
individuals.
The second approach takes advantage of linkage dis-
equilibrium (LD), that is the historical recombinants
between the disease mutation and the polymorphic vari-
ants surrounding the mutation. The extent of LD or
allelic association usually defines the area of the disease
locus.“Old”mutations show a short region of LD;more
recent,“young,”mutations are obviously associated with
a large region of LD because there were only few
meioses and generations to restrict the area of LD.LD is
useful in autosomal recessive disorders with consan-
guinity, or founder effect autosomal dominant and X-
linked disorders with ancient mutations.In contrast,LD
is not contributory in dominant or X-linked disorders
with many different and recent (only a few generations)
mutant alleles.
Positional identification of the pathogenic allele 
The next phase requires a search for mutant alleles of
genes that map within the critical interval.The method-
ology of this search for the elusive gene has changed
most dramatically in the last 12 to 15 years. The
advances of the human genome project provide a pub-
licly available genomic infrastructure that becomes
more detailed every year. In the mid-1980s, it was nec-
essary to complete the physical map of the critical
region, ie, to develop an overlapping set of cloned
human DNAs that covered the entire critical region.
Then, it was necessary to identify portions of all genes
in the critical interval, clone the entire cDNAs, and
determine the intron–exon junctions and their genomic
structure.All of the above steps have now been largely
accomplished by the international collaboration and
competition that is collectively called the human
genome project.This extraordinary project provided a
dense linkage map,
3 a complete physical map of the
genome,
12,13 a large number of partial gene sequences,
14
and, this year, the almost entire human genome
sequence.
4,5 At the time of writing (May 2001), there
exists in the public database a sequence of the human
genome that consists of about 40% finished high-qual-
ity sequence and ~50% draft sequence of lower quality
with numerous gaps and unordered DNA fragments.
Less than 10% of the human genomic sequence is still
unknown.There are two chromosomes, namely 22 and
21, for which the sequence is complete with only mini-
mal gaps.
6,7There are now catalogues of well-character-
ized and predicted genes in the entire genomic land-
scape. These catalogues are freely available and
constantly updated,for example,see the websites of the
National Center for Biotechnology Information and the
Ensembl project.
15,16 It is likely therefore that a sub-
stantial number of genes have already been identified in
the critical genomic interval that harbors the elusive
gene for the monogenic disorder of interest.The list of
genes is by no means complete and the characteriza-
tion of each gene is far from adequate; the genomic
efforts in the next couple of years will be directed
towards the structural and functional characterization
of all human genes.At present,however,the unfinished
gene list per genomic interval provides a wealth of can-
didates to search for mutations in the patients’ DNA
or RNA. The methodologies for mutation characteri-
zation have also changed considerably in the last few
years. Direct sequencing after polymerase chain reac-
tion (PCR) amplification of exons, intron–exon junc-
tions, 5'-untranslated region (UTR), and 3'-UTR usu-
ally detects the majority of mutations that may cause a
disease phenotype.Certainly,there are exceptions,and
sequencing after PCR amplification may miss muta-
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tions.A large, heterozygous deletion, for example, that
eliminates one or more exons,may go undetected with-
out a quantitative PCR,or by hybridization after South-
ern blotting. In some cases, it is necessary to separate
the two different alleles in vitro and search for muta-
tions in isolated alleles.
What is usually the result of a mutation search in an
“average” positional cloning project? A considerable
number of sequence variants are identified in the genes
sequenced.Since the frequency of polymorphic variants is
about 1 in 1300 nucleotides between two randomly cho-
sen chromosomes, approximately 40 nucleotide differ-
ences are expected to be found in the genes of the 1-Mb
critical region between normal and affected individuals.
This is based on the fact that about 2% of the genome is
a coding region of genes, and with the inclusion of
intron–exon junctions and 5'- and 3'-UTR,approximately
4% of the 1-Mb region is usually sequenced in patients.
The next important question is: which one of these
nucleotide differences is associated with (or is responsible
for) the disease phenotype? Several criteria could be
employed in order to focus on some of the differences.
• The presence of the variant nucleotide in normal indi-
viduals from the same ethnic group as the affected indi-
viduals is normally sufficient to consider these changes as
nonpathogenic variation.Usually,DNAs from about 100
individuals are examined for rare and common variants.
• The predicted consequence of the mutation is impor-
tant. Nucleotide differences resulting in nonsense
codons or translational frameshifts, or severe splicing
defects,are more likely to be pathogenic.
• De novo mutations,not present in the parents,partic-
ularly in sporadic cases of dominant or X-linked dis-
orders are more likely to be pathogenic.
• The most difficult to interpret nucleotide changes are
those that result in amino-acid substitutions (missense
mutations). Substitutions in evolutionarily well-con-
served amino acids among homologous proteins in dif-
ferent species are excellent candidates for pathogenic
mutations.
• Mutations that are predicted to alter the function of
the protein or have been experimentally demonstrated
to do so are excellent candidates.
• Certain mutations need to be tested in model organ-
isms in order to study their effect.
• Other mutations require long-term epidemiological
studies to prove their involvement with a disease phe-
notype.
The study of the molecular basis of the disease pheno-
type in unrelated pedigrees and the demonstration of
mutations in the same gene often confirm the involve-
ment of this gene in the disease.
The description of studies to elucidate the function of
the disease-related protein and the pathogenetic mech-
anism of the disease is beyond the scope of this article.It
is,however,important to emphasize that the evolution-
ary conservation of genes makes model organisms
(yeast,worm,fruitfly,zebrafish,or mouse) indispensable
tools for the functional analysis of human genes.
The methodology described above for gene cloning
responsible for monogenic disorders has been repeat-
edly successful.
2 A considerable number of disease-
related genes and alleles have been identified in the last
15 years. The OMIM contains 1168 genes with mutant
alleles associated with disease phenotypes.Most of these
have been identified using positional cloning efforts
without any previous knowledge of the biochemistry or
pathophysiology of the disease phenotype.
Functional gene variants 
for predisposition to common, 
complex, phenotypes
One of the greatest challenges of this decade for bio-
medicine is to identify the mutant/polymorphic alleles
that cause or predispose to common human disorders
with a strong genetic component. It is not far from the
truth if we state that the entire effort for the mapping,
sequencing,and determination of the normal variability
of our genome has been done in order to be able to
find the mutant alleles of the common, complex phe-
notypes. These phenotypes include disorders such as
schizophrenia and bipolar disease,diabetes,asthma,ath-
erosclerosis, multiple sclerosis, obesity, hypertension,
Alzheimer’s disease, aging, and susceptibility to infec-
tious diseases. The tasks appear enormous, but the
expected benefits for medicine could be so profound
that are certainly worth the effort and expenses from
both academia and industry.
The discovery of predisposing mutant alleles for com-
mon disorders is nevertheless very difficult. Although
we do not understand all the reasons for this difficulty,
we could certainly mention the following points.
First, the inheritance of the common complex pheno-
types is not clearly mendelian. It is true that there is an
aggregation of affected individuals in certain families,but the mode of inheritance is not compatible with the
usual recognizable patterns.On the other hand,there is
strong evidence for a genetic predisposition for these
complex disorders
17:(i) the frequency of these disorders
in relatives of affected individuals is much greater than
in the general population;and (ii) the frequency of con-
cordance in monozygotic twins is always greater than in
dizygotic twins.For some disorders,such as schizophre-
nia,adoption studies are also in favor of genetic predis-
position.In all of these studies,the underlying hypothe-
sis in favor of genetic predisposition is that people who
share a greater proportion of alleles have a higher prob-
ability of manifesting the disease in their lifetimes.
Monozygotic twins share 100% of their alleles; siblings
and dizygotic twins share 50% of their alleles; first
cousins share an eighth of their alleles.Therefore, for a
complex disease with genetic predisposition,the proba-
bility of developing the disease is greater in a monozy-
gotic twin of an affected individual,less in a sibling of an
affected individual, and even less in a first cousin. The
fact that the inheritance pattern of these disorders is not
mendelian renders the use of parametric linkage analy-
sis difficult or impossible, since these studies require a
fixed mode of inheritance.
Second,the phenotype may be uncertain.This is clearly
evident in the psychiatric disorders in which the diag-
noses are based only on clinical criteria.The danger of
misdiagnosis, or misclassification, is therefore consid-
erable. In addition, the age of onset of a phenotype is
variable even within the same family; this makes it dif-
ficult to categorize unaffected individuals as truly life-
time unaffected.A further problem is that there is likely
genetic heterogeneity in affected individuals within the
same family.This is because most of these disorders are
common and it is therefore possible to have affected
individuals due to the contribution of mutant alleles of
different genes. For example, it is not unusual to find
individuals with breast cancer not related to the BRCA1
gene belonging to families with well-documented
BRCA1-related breast cancer.After all,breast cancer is
common since it affects approximately 10% of females
in their lifetime.
Third,it is possible that each of the predisposing mutant
alleles has a minor effect on the phenotype and that
several mutant alleles from different genes in concert
result in a pathological phenotype.In addition,most of
the predisposing mutant alleles may be common poly-
morphic variants in the population.Unlike the successes
of the monogenic disorders, we know of very few
mutant alleles that predispose to common, complex
polygenic disorders.Such examples include the APOE4
allele, which predisposes to Alzheimer’s disease,
18 and
factor V Leiden, which predisposes to deep venous
thrombosis.
19
The most important challenge to the genetic medicine in
the next decade is certainly to uncover the mutant al-
leles that predispose to the complex common disorders.
The advances of the sequences of the human and other
genomes, and the discovery of the polymorphic vari-
ability among human genomes, provide the necessary
infrastructure to tackle these problems.In addition,the
development of rapid,high-throughput,inexpensive,and
reliable methods for mutation detection will also con-
tribute to these discoveries. Finally, the availability of
samples from a large number of parents, their family
members, and controls is also another necessary com-
ponent in this endeavor.
The methods that exist today for the mapping of pre-
disposing alleles (PDAs) could be summarized as fol-
lows (Figure 1).
20,21
Linkage analysis methods
The parametric methods with fixed mode of inheritance
could still be used in the large rare families segregating a
complex phenotype.Furthermore,linkage projects usually
involve small families with complex disorders, in which
case all possible modes of inheritance should be tested.
The nonparametric methods, also known as model-free
methods,are certainly more suitable for complex pheno-
types.These methods score the “amount”of shared alleles
among affected individuals.The most widely used method
is that of sibling pairs.In this,potentially interesting alle-
les are those that are shared in siblings in frequencies sta-
tistically different from the expected 50%.A large num-
ber of affected siblings are necessary (most studies used
100-200 such pairs) and their power to reveal linkage
increases when the DNAs of their parents are available.
There are several variations of this method, since all
affected relatives could be used and nonaffected individ-
uals could also provide valuable information.Most of the
studies with sibpairs use SSR markers because ideally all
four parental alleles could be recognized.For these stud-
ies, a genome-wide scan usually requires approximately
300 polymorphic markers placed in the average intervals
of average size 10 cM.
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This test, which is in between linkage and association,
estimates the difference between the alleles transmit-
ted and nontransmitted to patients from their parents.
The null hypothesis for a noncontributing locus is that
there is no difference between transmitted and non-
transmitted alleles. In this method, single affected indi-
viduals and their parents could be used (usually referred
as trios). Most studies have used about 100 such trios.
The advantage of this method is that it utilizes a power-
ful internal control of the nontransmitted alleles from
the same population as the affected alleles.
Association studies
The most simple study used to determine the implication
of a mutant allele to a phenotype is that of association of
the polymorphic allele to the phenotype.The polymorphic
allele (usually an SNP) could be PDA,or be within a very
short genomic distance from the PDA.The question then
is:how close could an SNP be to the PDA in order to still
detect an association, or LD? The answer to this ques-
tion is complex and depends on the number of the differ-
ent PDAs to the phenotype,the age of the mutant alleles,
the frequency of the mutant alleles in the population,the
heterogeneity of the phenotype,and the history and size
of the population.For example,the average blocks of LD
in European populations is approximately 60 kb around
common polymorphisms, whereas in the older African
human populations these blocks are much smaller.
22 It
follows that for an association study in the old popula-
tions,one needs many more polymorphic markers than in
younger populations.The isolated populations may also
provide an advantage since the blocks of LD may be even
larger; however, the disadvantage of these populations
may be that their PDAs are in different genes than those
of the outbred populations.
Most of the markers used in LD/association studies are
SNPs.Theoretically,the most useful SNPs are those that
change an amino acid, or occur in regions of gene
expression regulation. More than 2 million SNPs have
now been identified as part of the genome-sequencing
effort and a small fraction (0.2%) result in missense
codons.
4,7 It has been estimated that the average human
gene shows two to four common variants in the popula-
tion. It is perhaps more advisable at this stage to con-
centrate on the SNPs within genes and their regulatory
regions as markers for LD/association studies. In addi-
tion,many investigators recommend the use of two adja-
cent SNPs in concert as haplotypes (pattern of poly-
morphic alleles in one chromosome), in order to
increase the detective power of each site.The samples of
patients and controls used in association studies have
to be as identical as possible in terms of genome vari-
ability; ideally, the two samples need to be drawn from
the same ethnic group.The sample size is also a matter
of debate,but larger sample sizes provide more statisti-
cal power.It may well be necessary to collect samples of
several thousands of individuals per category.The sam-
ple size largely depends on the contribution of each
mutant allele to the phenotype, the number of genes
involved,the age of the mutant alleles,and the frequency
of the mutant PDAs in the unaffected population.
Joint linkage and association
In this approach, several genomic regions containing
PDAs are first identified by linkage analyses and then
LD/association studies are performed in the 10- to 20-
Mb critical regions.It is a common finding that the crit-
ical intervals from linkage studies of complex disorders
are 10 times larger than those of monogenic disorders,
even if considerable numbers of samples are used. In
addition,linkage and association studies of complex phe-
notypes reveal several (more than one) areas of sugges-
tive linkage, some of which could be replicated in sub-
sequent studies, but others could not be verified. (For a
recent discussion of the status of such studies in schizo-
phrenia and bipolar disease, see references 23 and 24,
respectively.)
Determination of the predisposing 
mutant alleles
How can we identify the predisposing mutant allele after
its mapping in the human genome? The answer to this
question may well be more difficult than the localization
of the PDA.Let us suppose that the PDA maps to a 100-
kb region of the genome.Within this interval,there may
well exist 100 common polymorphic alleles in the popu-
lation and a substantial number of these would be pre-
sent in the affected individuals. The determination of
those alleles with a significant contribution to the phe-
notype may require genotyping of additional affected
and unaffected individuals from different geoethnic
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13La investigación de variantes de alelos que
producen trastornos monogénicos o
predisponen a fenotipos poligénicos,
comunes y complejos
La investigación de genes mutantes para los tras-
tornos monogénicos ha significado un suceso
espectacular. Esto se ha podido realizar gracias al
mapeo e identificación de la secuencia del geno-
ma humano, la determinación de la variabilidad
de la secuencia, la serie de familias bien caracte-
rizadas con trastornos mendelianos, el desarrollo
de métodos estadísticos para el análisis de enlaces
y los métodos de laboratorio para la investigación
de mutaciones. El desafío actual de la medicina
genética es descifrar las variantes de las secuen-
cias de nucleótidos que predisponen a fenotipos
poligénicos, comunes y complejos. La metodolo-
gía para este desafío está en desarrollo y evolu-
ción constantes. Se puede anticipar que en los
próximos 10 a 20 años serán identificados los ale-
los susceptibles para estos trastornos frecuentes.
La recherche de variants alléliques
responsables de maladies monogéniques
ou prédisposant aux phénotypes
polygéniques courants complexes 
La recherche sur les gènes mutants des maladies
monogéniques a été un succès spectaculaire.
Celle-ci a été rendue possible grâce à l’établisse-
ment de la carte et du séquençage du génome
humain, à la détermination de la variabilité des
séquences, à la collecte de familles bien caracté-
ristiques porteuses de maladies mendéliennes et
au développement de méthodes statistiques pour
l’analyse de liaison ainsi que de méthodes de
laboratoire pour la recherche de mutations. Le
défi de la médecine  génétique est maintenant de
déchiffrer les variants de séquences nucléotides
qui prédisposent aux phénotypes polygéniques
courants complexes. La méthodologie pour y par-
venir est en cours de développement et en
constante évolution. Il est à prévoir que les gènes
de susceptibilité pour ces maladies courantes
seront identifiés dans les 10 à 20 ans à venir.
groups, the functional analysis of the variants, and large
epidemiologic studies. It is also possible that different
alleles in the same gene predispose to the phenotype,
similar to the situation in which different mutant alleles
within one gene cause the same monogenic phenotype.
Model organisms could also be used to map and clone
PDAs for common phenotypes.Due to space limitations,
the experimental strategies using animal models are not
discussed here.
Concluding remarks
The identification of mutant genes responsible for
monogenic disorders has been a triumph of medical
genetics in the last 15 years.These discoveries depended
on the successes of the mapping and sequencing of the
human genome, and identification of the normal vari-
ability. These achievements created an environment of
enthusiasm for further developments,high expectations,
and underestimation of the difficulties that lie ahead in
the complex,common phenotypes.
There is a cautious optimism now, in both academia and
industry,for further advances in the identification of these
functional sequence variants that predispose to the com-
mon human diseases.These will certainly continue to rev-
olutionize medicine and will place genetic medicine at the
center of the diagnosis and treatment of human disorders.
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